MabThera nabs NICE nod for leukemia

The U.K.'s cost-effectiveness watchdog has recommended Roche's top-selling cancer drug MabThera as a first line treatment for the most common form of adult leukemia. NICE recommends that the National Health Service pay for MabThera treatment only in combination with two specific chemo drugs. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.